Covid-19: Indian sites await DCGI nod to restart Oxford vaccine trial

Even as late-stage trials for the UK arm of the Oxford-AstraZeneca Covid-19 vaccine have been suspended after a study participant suffered a ‘potentially unexplained illness’, India will wait until the country’s drug regulator gives the go-ahead to restart the trials, observed investigators here.

The Drug Controller General of India (DCGI) V G Somani will take a call after he receives data from the Data and Safety Monitoring Board (DSMB) in the UK as well as India.

According to sources close to the development, around 100 participants were administered the first shot of the vaccine (Covishield) here. The safety data is being analysed